Industry ranking
QUOTIENT SCIENCES LIMITED exhibits a consistent trend of delayed payments, with 93% of invoices categorized as late despite an average payment time of 29 days. While 51% of payments are made within 30 days, a substantial 44% extend into the 31-60 day range, and 5% exceed 60 days, indicating a regular trajectory towards prolonged payment cycles.
The high rate of late payments (93%) indicates significant unreliability in payment timing, making it difficult for suppliers to predict when funds will be received. This pattern introduces considerable cash flow risk for suppliers, as nearly half of all invoices are paid beyond 30 days, demonstrating consistent unpredictability in payment adherence.
Suppliers should exercise caution when engaging with QUOTIENT SCIENCES LIMITED due to the very high probability of experiencing payment delays. It is recommended that suppliers mitigate risk by implementing stricter payment terms, such as upfront deposits or shorter net terms, and closely monitoring outstanding invoices to manage potential cash flow impacts.
| Reporting Period | Filing Date | Average Time to Pay (days) | Paid within 30 days | Paid 31-60 days | Paid after 60 days | Not Paid within Terms |
|---|---|---|---|---|---|---|
| 01 Jul 2025 - 31 Dec 2025 | 30 Jan 2026 | 36 | 36% | 55% | 9% | 72% |
| 01 Jan 2025 - 30 Jun 2025 | 31 Jul 2025 | 37 | 35% | 53% | 12% | 70% |
| 01 Apr 2024 - 31 Dec 2024 | 31 Jan 2025 | 29 | 51% | 44% | 5% | 93% |
| 01 Oct 2023 - 31 Mar 2024 | 25 Apr 2024 | 27 | 56% | 36% | 8% | 75% |
| 01 Apr 2023 - 30 Sept 2023 | 31 Oct 2023 | 26 | 53% | 41% | 6% | 72% |
| 01 Oct 2022 - 31 Mar 2023 | 26 Apr 2023 | 30 | 54% | 38% | 8% | 70% |
| 01 Apr 2022 - 30 Sept 2022 | 01 Nov 2022 | 30 | 44% | 50% | 6% | 76% |
| 01 Oct 2021 - 31 Mar 2022 | 20 Apr 2022 | 19 | 71% | 25% | 4% | 82% |
| 01 Apr 2021 - 30 Sept 2021 | 26 Oct 2021 | 34 | 36% | 54% | 10% | 75% |
| 01 Oct 2020 - 31 Mar 2021 | 29 Apr 2021 | 39 | 26% | 67% | 7% | 81% |
| 01 Apr 2020 - 30 Sept 2020 | 19 Oct 2020 | 24 | 58% | 38% | 4% | 66% |
| 01 Oct 2019 - 31 Mar 2020 | 30 Apr 2020 | 35 | 38% | 53% | 9% | 76% |
| 01 Apr 2019 - 30 Sept 2019 | 30 Oct 2019 | 48 | 29% | 57% | 14% | 76% |
| 01 Oct 2018 - 31 Mar 2019 | 30 Apr 2019 | 25 | 70% | 28% | 2% | 87% |
| 01 Apr 2018 - 30 Sept 2018 | 30 Oct 2018 | 40 | 26% | 69% | 5% | 80% |
This information is as reported by the business, and responses are in their own words.
Standard payment terms
payment 30 days after invoice date
Were there any changes to the standard payment terms in the reporting period?
No information available
Any other information about payment terms
No additional information
Maximum contractual payment period agreed
90
Quotient will always seek to resolve any disputes informally in the first instance. Where this is not possible, formal proceedings may be initiated after paying due regard to any Alternative Dispute Resolution clauses stipulated in the relevant contracts.
Has this business signed up to a code of conduct or standards on payment practices?
For example, signatories to The Prompt Payment Code must commit to paying 95% of their invoices within 60 days.
❌
Does this business offer e-invoicing in relation to qualifying contracts?
This is where suppliers can electronically submit and track invoices. It's not just allowing suppliers to email them an invoice.
❌
Does this business offer supply chain finance?
This is where a supplier who has submitted an invoice can be paid by a third-party finance provider earlier than the agreed payment date. The business would then pay the finance provider the invoiced sum.
❌
Under its payment practices and policies, can this business deduct sums from payments under qualifying contracts as a charge for remaining on a supplier list?
❌
During the reporting period, did the business deduct sums from payments as a charge for remaining on a supplier list?
No information available
Quotient Sciences Limited is registered in Ruddington, Nottingham, and its stated business activity is research and experimental development on biotechnology. Companies House records show the company has previously traded as Quotient Clinical Limited and, before that, as Pharmaceutical Profiles Group Limited, reflecting a history in pharmaceutical development and clinical research. Filing history shows the company operates as part of a wider corporate group, with Quad Uk Bidco Limited recorded as a person with significant control. The company remains active, filing accounts and confirmation statements up to 2024 and 2025 respectively. No further detail on specific services or client base is available from the supplied evidence.
Generated from the company's website and Companies House records. Sources: find-and-update.company-information.service.gov.uk · find-and-update.company-information.service.gov.uk